A5019172032- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- Pharmaceutical studies and practices
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Genomics and Rare Diseases
- Hematopoietic Stem Cell Transplantation
- Immune cells in cancer
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Single-cell and spatial transcriptomics
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Adolescent and Pediatric Healthcare
- Lung Cancer Research Studies
- Melanoma and MAPK Pathways
- Cancer-related Molecular Pathways
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Neuroblastoma Research and Treatments
- COVID-19 and healthcare impacts
Emory University
2015-2025
Children's Healthcare of Atlanta
2016-2025
Aflac (United States)
2017-2023
Center for Cancer and Blood Disorders
2017
Summary Treatment with dose‐adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab ( DA ‐ ‐R) has become the standard of care for primary mediastinal B‐cell lymphoma PMBCL ) at many institutions despite limited data in multi‐centre setting. We report a large, retrospective analysis children adults treated ‐R to characterize outcomes evaluate prognostic factors. assessed 156 patients across 24 academic centres, including 38 118 adults....
Acute myeloid leukemia (AML) microenvironment exhibits cellular and molecular differences among various subtypes. Here, we utilize single-cell RNA sequencing (scRNA-seq) to analyze pediatric AML bone marrow (BM) samples from diagnosis (Dx), end of induction (EOI), relapse timepoints. Analysis Dx, EOI scRNA-seq, TARGET RNA-seq datasets reveals an blasts-associated 7-gene signature (CLEC11A, PRAME, AZU1, NREP, ARMH1, C1QBP, TRH), which validate on independent datasets. The analysis distinct...
Abstract Background We sought to determine the feasibility of co‐administering everolimus with a four‐drug reinduction in children and adolescents acute lymphoblastic leukemia (ALL) experiencing first marrow relapse. Procedure This phase I study tested vincristine, prednisone, pegaspargase doxorubicin patients relapse occurring >18 months after complete remission (CR). The primary aim was identify maximum tolerated dose everolimus. Three levels (DLs) were during escalation (2, 3, 5 mg/m 2...
Despite a remarkable increase in the genomic profiling of cancer, integration discoveries into clinical care has lagged behind. We report feasibility rapid identification targetable mutations 153 pediatric patients with relapsed/refractory or high-risk leukemias enrolled on prospective trial conducted by LEAP Consortium. Eighteen percent had high confidence Tier 1 2 recommendation. describe responses 14% leukemia who received matched targeted therapy. Further, order to inform future therapy...
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of remission failure, relapse, and death due to leukemia, despite intensive therapies. Infant KMT2A-r ALL blasts characterized by DNA hypermethylation. Epigenetic priming methyltransferase inhibitors increases the cytotoxicity chemotherapy in preclinical studies. The Children’s Oncology Group trial AALL15P1 tested safety tolerability five days azacitidine immediately...
ABSTRACT INTRODUCTION Vincristine sulfate liposome injection (VSLI), a liposomal formulation of vincristine, may be better tolerated than standard aqueous vincristine and enable dose intensification. PROCEDURES Based on single‐agent tolerability, activity, FDA approval in adults with acute lymphoblastic leukemia (ALL), we tested the safety feasibility VSLI as replacement for UK ALL R3 mitoxantrone‐based four‐drug induction (Cohort A), three‐drug anthracycline‐free B), maintenance...
Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma, with dismal prognosis despite therapies. New approaches are needed for those refractory disease. PBL expresses antigens similar to multiple myeloma (MM), including maturation antigen (BCMA). Chimeric receptor T-cell (CAR-T) therapy directed against BCMA has shown efficacy the treatment heavily pretreated MM low rates grades 3 and 4 cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity...
Mercaptopurine (6‐mercaptopurine, 6MP) is a mainstay of curative therapy in childhood acute lymphoblastic leukemia (ALL), and contributes to its 90% overall survival rate. We present two patients with ALL who suffered severe pancreatitis secondary 6MP. Through the use allopurinol conjunction reduced dose 6MP, we were able continue 6MP without further pancreatitis. This report small body literature on associated describes novel approach continued during therapy.
BACKGROUND Hyperleukocytosis is a serious, life‐threatening complication of pediatric acute leukemia that can cause neurologic injury, pulmonary leukostasis, metabolic derangements, and coagulopathy. Acute has the highest risk mortality morbidity at presentation when associated with hyperleukocytosis. Infant presents unique challenges treatment considerations due to disease itself size overall health patient. While medical management hyperleukocytosis in older patients been described,...
PURPOSE Profiling of pediatric cancers through deep sequencing large gene panels and whole exomes is rapidly being adopted in many clinical settings. However, the most impactful approach to genomic profiling remains be defined. METHODS We conducted a prospective precision medicine trial, using whole-exome tumor germline tissue whole-transcriptome (RNA Seq) characterize mutational landscape 127 tumors from 126 unique patients across spectrum brain tumors, hematologic malignancies,...
Abstract Background Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in childhood. Survival for patients following relapse remains poor, and achieving complete remission (CR) after first critical step to cure. Carfilzomib a proteasome inhibitor with an acceptable safety profile clinical activity adults multiple myeloma but has not been assessed children. The primary objective of this phase 1b study was assess tolerability carfilzomib combined vincristine, dexamethasone,...
Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but approximately 40% of patients who relapse continue to poor outcomes. A combination checkpoint-inhibitor nivolumab and azacitidine has demonstrated improvements median adults with AML. This phase I/II study children relapsed/refractory AML (NCT03825367) was conducted through Therapeutic Advances Childhood Leukemia & Lymphoma consortium. Thirteen patients, age 13.7 years, were...